Sapacitabine
- Generic Name
- Sapacitabine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C26H42N4O5
- CAS Number
- 151823-14-2
- Unique Ingredient Identifier
- W335P73C3L
- Indication
Investigated for use/treatment in solid tumors, cutaneous t-cell lymphoma, myelodysplastic syndrome, and leukemia (lymphoid).
- Associated Conditions
- -
- Associated Therapies
- -
Olaparib + Sapacitabine in BRCA Mutant Breast Cancer
- First Posted Date
- 2018-08-22
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 10
- Registration Number
- NCT03641755
- Locations
- ๐บ๐ธ
Broad Institute of MIT, Cambridge, Massachusetts, United States
๐บ๐ธDana Farber Cancer Institute, Boston, Massachusetts, United States
A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia
- First Posted Date
- 2011-02-25
- Last Posted Date
- 2022-06-22
- Lead Sponsor
- Cyclacel Pharmaceuticals, Inc.
- Target Recruit Count
- 482
- Registration Number
- NCT01303796
- Locations
- ๐บ๐ธ
Rush University Medical Center, Chicago, Illinois, United States
๐บ๐ธThe University of Chicago Medical Center, Chicago, Illinois, United States
๐บ๐ธSt. Francis Medical Group Oncology and Hematology Specialists, Indianapolis, Indiana, United States
Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23)
- Conditions
- Interventions
- First Posted Date
- 2010-12-03
- Last Posted Date
- 2019-09-06
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 18
- Registration Number
- NCT01253460
- Locations
- ๐บ๐ธ
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
A Study of Oral Sapacitabine in Patients With Previously Treated Non-Small Cell Lung Cancer
- First Posted Date
- 2009-04-22
- Last Posted Date
- 2021-12-22
- Lead Sponsor
- Cyclacel Pharmaceuticals, Inc.
- Target Recruit Count
- 62
- Registration Number
- NCT00885963
- Locations
- ๐บ๐ธ
Rush University Medical Center, Chicago, Illinois, United States
๐บ๐ธPenn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States
A Randomized Phase II Study of Oral Sapacitabine in Patients With Advanced Cutaneous T-cell Lymphoma
- First Posted Date
- 2007-05-22
- Last Posted Date
- 2021-12-22
- Lead Sponsor
- Cyclacel Pharmaceuticals, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT00476554
- Locations
- ๐บ๐ธ
Stanford University Hospitals and Clinics, Stanford, California, United States
๐บ๐ธTimothy Kuzel, M.D., Chicago, Illinois, United States
๐บ๐ธThe University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Safety and Pharmacology Study of Sapacitabine to Treat Advanced Leukemias or Myelodysplastic Syndromes
- First Posted Date
- 2006-09-26
- Last Posted Date
- 2021-12-13
- Lead Sponsor
- Cyclacel Pharmaceuticals, Inc.
- Target Recruit Count
- 47
- Registration Number
- NCT00380653
- Locations
- ๐บ๐ธ
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.